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1 Introduction
The debate about parallel imports (PI) and the views on their impact in the global
economy have become increasingly controversial in recent years. Generally defined,
PI are unauthorized re-imports of genuinely produced commodities back to the coun-
try of the original producer. The issue has by and large been associated with price
discrimination, vertical price control, and national price regulations.1 When goods
sold by a patent holder to a foreign market at a lower price are imported back to the
original country, the producer faces competition with its own goods offered at a lower
price. This also reveals an important connection between PI and the protection of
intellectual property rights (IPR).
In this paper, we aim to explore the effect of PI on innovation in emerging
economies with TRIPS obligations to upgrade their IPR regime. Entering a market
where IPR are not respected enables foreign manufacturers to imitate and send a
part of their output back to the original market to exploit an arbitrage opportunity.
While consumers may gain from lower prices, this may provoke consequences on the
innovative behavior of different type of firms, and hence the fate of the industry.
The Patent Act 2005 of India created major concerns in the pharmaceutical
industry, one of its greatest points of strength since decades. While generic drugs
have been freely and skillfully produced in India, the Patent Act prohibited the
production of generics whose patents have not expired.2 On the optimistic side, this
can be a first step towards taking a leading role in innovating original medicine. It
could however be accompanied by a sudden surge in prices of pharmaceuticals in
India and hence limited access to medicine by a great portion of the population.
Interestingly, according to the TRIPS agreement each WTO member has the
sovereignty to choose its own policy on PI. This could be seen as an opportunity
to mitigate the negative effects of IPR protection on consumers, made possible by
allowing imports of generic products from a market still unregulated in terms of
IPR. There have been rather skeptic views with regards to PI in the international
trade literature, precisely for cases such as the rapidly evolving Indian pharmaceu-
tical industry. In particular, an important question that has been raised is: “does
allowing PI reduce R&D by Indian pharmaceuticals, and thereby impede the road
taken towards the development of its own innovative rather than an imitative phar-
1See Maskus and Chen (1994), Richardson (2002), Valletti (2006), Ganslandt and Maskus (2007)
and Grossman and Lai (2008).
2All patents registered before 1995 cannot be protected in India despite being protected else-
where. Therefore, they could still be produced as generics in India.
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maceutical industry?”
To account for the particular characteristics of the Indian pharmaceutical in-
dustry, we separate the market into two groups: (i) large scale companies such as
Ranbaxy, Dr. Ready, or Cipla, which pursue a catch up strategy by engaging in
innovation in order to challenge leading firms in developed countries; (ii) medium
firms such as Lincoln, Simrone, and Aurochem, commonly referred to as specialized
operators.3 Both types of firms possess patents, but differ with respect to their
R&D capabilities. The more efficient large scale companies are competent to enter
less risky regulated markets such as the US or the EU. On the other hand, medium
firms are technologically inferior and seek new unexploited markets to compensate
for their competitive disadvantage. Such destination markets are often unregulated,
where local manufacturers can reproduce and sell imitation products back in the
original market.
A good example of such unregulated market is Tanzania, which under TRIPS is
not required to enforce IPR in pharmaceuticals until 2016.4 In addition, it is the
only new frontier in Africa since 2002 with capabilities to replicate active principle
ingredients (API) besides Egypt, which has been active since 1992. There are 32
other African countries, which are only capable of producing formulations. As for-
mulation manufacturing already exists in Tanzania, workers in Indian subsidiaries
may defect and disseminate information to local manufacturers. They can then use
their absorptive capacity to produce the similar final good that contains the patented
API and sent it back to India.
The literature on the impact of PI on innovation is rare and mostly focuses on
the R&D decision of a monopolist when its distributor engages in PI. Innovation has
been modelled in several forms with mixed results. Valletti and Szymanski (2006)
look at product innovation, where more R&D translates into higher quality products.
They find the impact of PI to be negative on R&D incentives, even if the monopolist
may introduce a new lower quality brand to compete with the generic drug. Li and
Robles (2007) instead find the conditions under which PI increases incentives to
innovate a new horizontally differentiated version of the product. Li and Maskus
(2006) consider cost reducing process innovation and show that PI always inhibits
R&D. Li (2006) adds to this by examining competition between two symmetric firms
in the home country and finds ambiguous results on innovation that depending on
3See Chaudhuri (2005a, 2005b).
4 India holds the highest number of registered patents in Tanzania and accounts for 1315 drug
products registered there in 2007, which is more than one third of the total. Kenya is ranked second
with 307 registered drugs. See Chaudhuri (2008) for more details.
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transportation cost. The results in the above work are derived under the implicit
assumption that IPR are perfectly enforced across the globe.
We build a theoretical framework to study the consequences of PI on innovation
in the context of an emerging market, such as the Indian pharmaceutical indus-
try. In particular, we analyze the strategic innovative activities of technologically
asymmetric firms competing in the home country to understand the impact of PI
from an unregulated market where IPR are not protected. We choose to focus on
process innovation as we believe it is more appropriate for describing an emerging
economy. Indeed, a detailed analysis of the Indian pharmaceutical industry before
and after the Patent Act shows a remarkable increase in process innovation whereas
no new product has been introduced in this period (Arora, Branstetter and Chat-
terjee, 2008). Our main contribution lies in introducing features to study PI in
such developing markets, namely asymmetric technologies and imperfect IPR en-
forcement, which together shed light on a number of noteworthy implications absent
from previous literature.
More precisely, our model adopts the concept of Leahy and Neary (1997) and
Zigic (1998) to build a two stage game where firms invest in cost-reducing innovation
and compete in quantity. We build a three country model with two heterogeneous
firms located in the home market. The more technologically advanced firm serves
a regulated foreign market, whereas the less efficient firm enters an unregulated
one. By comparing the optimal R&D investment with and without PI from the
unregulated market, we demonstrate that R&D investment by each type of firm
crucially depends on the extent of firm heterogeneity and trade costs.
We find that the damages from PI are absorbed by the large firm under free
trade, reducing R&D effort by both firms. Trade costs tend to transfer the burden
brought about by PI in terms of lower market share to the medium firm. This gives
significance to competition in the home market, where PI creates a ’domino’ effect
inducing the technologically superior firm to strategically increase its R&D. On the
other hand, it is the foreign market that plays the principal role in the R&D decision
of the medium firm. PI encourages R&D investment by the technologically inferior
firm when it increases its foreign sales, which is more likely to occur for low degrees
of firm heterogeneity. Finally, we show that tariffs can only make the international
exhaustion system welfare optimal if the technology gap between firms is large. This
could explain why allowing PI may be justified in India, but not in Europe or the
US.
The paper is structured as follows. Section 2 describes the basics of the model.
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Section 3 solves the game with and without a ban on PI. Section 4 compares the two
scenarios to analyze the incentives to innovate by each firm and derives implications
for welfare. Section 5 concludes.
2 The Basic Framework
Consider a home country H, where two heterogeneous firms, L and M , compete.
In our example of the Indian pharmaceutical industry, L represents a large-scale
company while M represents a medium firm, which obtains its patent through the
so called "me-too" drugs, i.e. drugs that imitate existing products and consist
of only minor modifications.5 While both firms can invest in cost-reducing R&D
activity, they differ in their ability to perform R&D. We assume that L enjoys a
superior production technology due to prior experience in the field. We abstract
from product differentiation and assume full homogeneity between the two goods in
the eyes of consumers.6
There are two segmented foreign markets, the North and the South, labeled N
and S respectively. IPR are protected in N and H, while S remains an unregulated
market. We assume that in addition to the home market, firm L serves the North,
where it does not face the threat of imitation.7 On the contrary, firm M enters the
unexploited Southern market, where IPR are not recognized.8 Local manufacturers
in S could hence freely reproduce the drug and sell it not only in S, but also export to
H at cost t giving rise to PI. We consider only one firm in S and assume that it does
not possess the technology to engage in cost-reducing R&D.9 The home government
has the possibility to ban PI or allow it if it considers that social welfare is damaged
by such a practice.
5This is for instance incremental innovation to the product, which has already been invented by
the big firm. Thus, no initial large fixed cost are involved.
6This is done so without the loss of generality as the results remain the same even when products
are not fully homogeneous.
7Adding a Northern market into the model also serves to avoid creating an unbalanced market
size bias in favor of the M firm.
8We can think of FDI as the mode of serving the foreign market. Adding a symmetric fixed cost
of FDI will not alter the framework as both L and M have an addtional foreign market both under
PI and no PI.
9This reflects the fact that foreign goods in less developed countries comprise a large fraction of
sales compared to local production ( for evidence in Tanzania, see Chaudhuri, 2008). In our model,
this comes due to the cost advantage of the medium firm with respect to the less efficient local firm.
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We adopt the familiar linear demand function for each country:
pi = a−Qi i = H,N, S. (1)
For the sake of simplicity, markets are equal in size, captured by a. Depending on
whether PI is allowed or not, either two or three firms operate in H. The L firm
enjoys a monopoly position in N due to the enforcement of IPR, while the M firm
competes with a local firm in S. More precisely,
QH ≡
{
QNPH = qLH + qMH
QPIH = qLH + qMH + qSH
,
QN = qLN , (2)
QS = qMS + qSS ,
where the first subscript of q denotes the type of firm, and the second the market it
serves. Superscripts NP and PI specify the scenario in which parallel imports are
banned and allowed respectively.
The cost function for each firm is
cL = c− 1
2
√
xL ,
cM = c− β
2
√
xM , (3)
c
S
= c,
where investment in cost reducing innovation is indicated by xL and xM for the
L and M firms. Parameter c is the pre-innovation production cost equal across
firms. We assume that the lack of IPR protection in S allows the Southern firm to
imitate the product, but not the production process. Parameter β ∈ [0, 1] captures
the technological difference between the large-scale and the medium firm.10 Finally,
a > c, xL ≤ 4c2 and xM ≤ 4
(
c
β
)2
hold to assure non-negative marginal costs after
innovation.
The profit function for the L and M firms are
πL = (pH − cL)qLH + (pN − cL)qLN − xL, (4)
π
M
= (pH − cM)qMH + (pS − cM)qMS − xM . (5)
The profit of the Southern firm is:
π
S
≡
{
πNP
S
= (pS − cS)qSS
πPI
S
= (pS − cS)qSS + (pH − cS − τ)qSH
. (6)
10Alternatively, one can think of (1− β) as the technology gap between the two firms.
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3 Solving the Game
The two firms in H play a two-stage game: in the first stage they invest in process
R&D and in the second stage they compete in quantity à la Cournot. We solve the
game first in the case where PI is forbidden and then in the case where it is allowed.
3.1 No Parallel Import
We start by considering the case in which PI is banned. Using backward induction,
second stage optimal quantities as a function of R&D investment can be computed
by taking the first order conditions of (4) and (5) using (1), (2) and (3):
qLH (xL, xM) =
a− c
3
+
2
√
xL − β√xM
6
,
qMH (xL, xM) =
a− c
3
+
2β
√
xM −√xL
6
,
q
LN
(xL, xM) =
a− c
2
+
√
xL
4
(7)
q
MS
(xL, xM) =
a− c
3
+
β
√
xM
3
q
SS
(xL, xM) =
a− c
3
− β
√
xM
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By substituting the above expressions into the original home profit functions, we
solve for the optimal R&D investments by maximizing with respect to xL and xM
to get11
x∗L =
[
6(51− 14β2)
1071− 242β2
]2
, (8)
x∗M =
[
221β
1071− 242β2
]2
. (9)
Innovation by the L firm is decreasing, while that of M is increasing in β, i.e.
with a lower technological gap. Substituting β = 1 in (8) and (9) reveals that the
technologically superior firm always invests more in R&D, i.e. x∗L > x
∗
M .
12
11For the sake sake of exposition, we can eliminate (a − c) from the final form equations as it
appears in a multiplicative form in front of all optimal values of R&D investment, quantity, and
profit.
12Recall that the L firm enjoys a monopoly position in its foreign market N , whereas the M firm
competes in a duopoly in S,
7
Substituting (8) and (9) in (7), optimal quantities can be calculated and are
q∗LH =
3(306− 97β2)
2(1071− 242β2) , q
∗
LN
=
2(306− 71β2)
1071− 242β2 ,
q∗MH =
306 + 7β2
1071− 242β2 , q
∗
MS
=
7(51− β2)
1071− 242β2 , (10)
q∗SS =
714− 235β2
2(1071− 242β2) .
The derivatives of the optimal quantities w.r.t. β convey the expected results that
∂q∗Li/∂β < 0, ∂q
∗
SS
/∂β < 0 and ∂q∗Mi/∂β > 0, for i = L,M . Note that a higher β
not only reduces the productivity gap between L and M , but also gives M a higher
technological edge over the Southern firm in S.
Plugging the optimal R&D investments and quantities back into (4) and (5)
yields optimal profits:
π∗L = (q
∗
LH
)2 + (q∗LN )
2 − x∗L, (11)
π∗M = (q
∗
MH
)2 + (q∗MS)
2 − x∗M . (12)
As with the innovation efforts, profit of the L firm is decreasing, while that of
the M firm is increasing in β: ∂π∗L/∂β < 0 and ∂π
∗
M/∂β > 0.
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Finally, consumer surplus in the home country without PI amounts to
CS∗H =
(q∗LH + q
∗
MH
)2
2
, (13)
and is increasing in β.The direct effect of β on q∗MH outweighs its indirect effect on
q∗LH , i.e.
∣∣∣∂q∗MH/∂β∣∣∣ > ∣∣∣∂q∗LH/∂β∣∣∣ , as it can be easily ascertained.
3.2 Parallel Import
We now look at the case in which PI is allowed into the home country, where τ =
t(a− c) is the trade cost normalized by the size of the market. As in the previous
scenario, second stage optimal quantities can be calculated and are:
qLH (xL, xM) =
a− c+ τ
4
+
3
√
xL − β√xM
8
,
qMH (xL, xM) =
a− c+ τ
4
+
3β
√
xM −√xL
8
, (14)
q
SH
(xL, xM) =
a− c− 3τ
4
− β
√
xM +
√
xL
8
,
where qLN (xL, xM), qMS (xL, xM), and qSS (xL, xM) take the same form as in (7).
13All explicit expressions for both regimes are presented in Appendix I.
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Next, we derive the optimal R&D investments, which are:
x∗∗L =
[
2(1008− β2[298 + 129τ ] + 432τ)
3(2448− 623β2)
]2
, (15)
x∗∗M =
[
2β(235 + 108τ)
2448− 623β2
]2
, (16)
Innovation by both firms is always increasing in trade costs τ . Similar to the no
PI case, innovation by the L firm is decreasing, that of M is increasing in β, and
x∗∗L > x
∗∗
M is always true.
Optimal quantities are in turn:
q∗∗LH =
864− β2[289 + 215τ ] + 720τ
2448− 623β2 , q
∗∗
LN
=
8352− β2[2167 + 129τ ] + 432τ
2448− 623β2 ,
q∗∗MH =
8(198 + β2[17− 24τ ] + 216τ)
3(2448− 623β2) , q
∗∗
MS
=
3(272− β2[17− 24τ ])
2448− 623β2 , (17)
q∗∗SS =
2(408− β2[143 + 18τ ])
2448− 623β2 , q
∗∗
SH
=
1584− β2[569− 1353τ ]− 1656τ
3(2448− 623β2) .
Comparative statics with respect to β replicate the mechanism at work under no PI.
Additionally, ∂q∗∗SH/∂β < 0 as entering the home market is easier when the M firm
is weak. Clearly, trade costs τ expand output by the home firms and reduce that by
the foreign firm: ∂q∗∗SH/∂τ < 0, ∂q
∗∗
HH
/∂τ > 0, ∂q∗∗MH/∂τ > 0.
Notice that there is a prohibitive level of trade costs that blocks PI by making
q∗∗SH = 0, which is
τˆ =
(1584− 569β2)
3(1872− 451β2) . (18)
This threshold level of trade costs starts at τˆ |β=0 ≃ 0.28 and monotonically falls to
τˆ |β=1 ≃ 0.24. Clearly, we are only interested in parameter values of τ < τˆ , where
PI is a feasible option,
Optimal profits for L and M in the presence of PI are:
π∗∗L = (q
∗∗
LH
)2 + (q∗∗LN )
2 − x∗∗L , (19)
π∗∗M = (q
∗∗
MH
)2 + (q∗∗MS)
2 − x∗∗M . (20)
The comparative statics of profits work in the same direction as in the case with
no PI, with the addition that profits of both firms are increasing in trade costs τ .14
Finally, consumer surplus in the home country is:
CS∗∗H =
(q∗∗LH + q
∗∗
MH
+ q∗∗SH )
2
2
, (21)
14 In a different context under demand uncertainty, Raff and Schmitt (2007) show how PI may
incrase the profit of manufacturers.
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which is increasing in β and decreasing in τ . The former is because the positive direct
effect of β on the output ofM dominates the negative indirect effect on the quantity
produced by the other firms:
∣∣∣∂q∗∗MH/∂β∣∣∣ > ∣∣∣∂(q∗∗LH + q∗∗SH )/∂β∣∣∣. A similar argument
applies to the direct effect of τ on the imports of the Southern firm:
∣∣∣∂q∗∗SH/∂τ ∣∣∣ >∣∣∣∂(q∗∗LH + q∗∗MH )/∂τ ∣∣∣.
4 Analysis and Policy Implication
4.1 The Impact on Innovation
Taking into account the role of both technological heterogeneity between firms and
trade costs, we compare the innovation effort carried out by firms across the two
regimes. The critical levels of τ above which PI increases cost-reducing R&D by L
and M can be found using (8), (9), (15) and (16), and are respectively:
τL =
44064− 31311β2 + 6382β4
3(1071− 242β2)(144− 43β2) , (22)
τM =
12546− 7981β2
72(1071− 242β2) , (23)
where τL < τM < τˆ for β ∈ [0, 1]. Hence,
Lemma 1 Allowing PI is more likely to stimulate innovation by the more techno-
logically advanced firm as ∆xL = x
∗∗
L −x∗L > 0 for τ > τL, ∆xL = x∗∗M −x∗M >
0 for τ > τM , where τM > τL.
Proof Directly follows by inspecting (22) and (23). 
Lemma 1 is illustrated with the aid of Figure 1, where the above threshold values
determine the partition of the parameter space. The figure can be divided into three
regions: A, B, and C.
Region A depicts a situation of free trade or low values of τ . PI decreases
R&D by both firms due to added competition coming from imports of the Southern
firm. Introducing PI reduces the market share of L and M in the home market
(∆qLH = q
∗∗
LH
− q∗LH < 0 and ∆qLM = q∗∗MH − q∗MH < 0), more so the lower the value
of β.15 This is the case because imports from the South are at their highest level
when the M firm is relatively inefficient.
15The difference between the variables of interest across the two regimes can be found in Appendix
II.
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Figure 1: Innovation
τ
0.2
β
τL
τM
10
A
C
B
∆xL < 0
∆xM < 0
∆xL > 0
∆xM < 0
∆xL > 0
∆xM > 0
Imports tend to absorb more market share from the L firm as long as
τ < τ˜ ≡ 88128− 175536β
2 + 84593β4
6(1071− 242β2)(144− 151β2) ⇐⇒ |∆qLH | > |∆qMH | , (24)
with τ˜ < τL in β ∈ [0, 1].16 Increasing trade costs shifts the burden of PI from the
L to the M firm and this is confirmed by:
∂(|∆qLH | − |∆qMH |)
∂τ
= −(144− 151β
2)
2448− 623β2 < 0. (25)
We can therefore state:
Proposition 1 While for low τ the reduction in market share brought by PI affects
more the L firm, increasing τ transfers the burden to the M firm. Given
Lemma 1, when trade costs are sufficiently large so that τ > τL, introducing
PI increases R&D investment by the L firm.
Proof Directly follows from (24) and (25).
16The threshold value τ˜ starts at τ |
β=0
≃ 0.1 and goes to zero for β ≃ 0.9.
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Proposition 1 explains how trade costs affect the market size perceived by each
firm, which in turn determines the incentives to engage in process innovation. When
trade costs protect L to give a sufficiently large edge overM , the former invests more
than under the no PI case. This entails a shift from region A to region B in Figure
1, and occurs when trade costs reach τ = τL.
While allowing PI results in more R&D investment by L in region B, it reduces
that byM . Here, the foreign entrant steals more market share from the ’vulnerable’
M creating a "domino effect" by making L more aggressive and stimulating its
innovation effort. In region B, the Southern market starts to play a crucial role in
the R&D decision of M . Interestingly, solving ∆qMS = q
∗∗
MS
− q∗MS for τ unveils that
PI induces M to increase its output destined for the South when τ > τM . This is
more likely to occur when the technology gap between L and M is not significant,
since ∂τM/∂β < 0.
Using this result along with Lemma 1 confirms that PI encourages also M to
devote more resources to R&D exactly when ∆qMS > 0. It follows that:
Proposition 2 Allowing PI from the South to the home market increases the out-
put of the M firm for the Southern market along with its R&D efforts when
τ > τM . This is more likely for relatively high values of β.
Proof Directly follows from (23), and ∆qMS evaluated in Appendix II.
Proposition 2 suggests that PI may instigate M to increase its production for
the South and this is viable when it enjoys a large cost advantage with respect to
the Southern firm. If so, we move to region C, where a combination of sufficiently
high values of β and τ induces more process R&D by both firms under PI. In
line with recent PI literature, our results reinforce the claim that PI may actually
enhance incentives to innovate by home firms. It remains to evaluate whether PI
also improves aggregate welfare in the home country.
4.2 The Impact on Welfare
Let us first consider the case where trade costs do not generate revenues to the home
government. It follows that social welfare in H amounts to the sum of consumer
and producer surplus: WH = CSH +ΠH , where ΠH = πL + πM .
First of all, in the admissible range of trade costs τ ∈ [0, τˆ ] , we can demonstrate
that
∆CSH = CS
∗∗
H −CS∗H > 0, (26)
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as the entry of a third firm into the home market always makes consumers better
off.17 Together with the results from the previous section on R&D, PI may eliminate
the conventional trade-off between consumers’ well-being and firms’ incentive to
innovate (area C in Figure 1). Nevertheless, looking at the supply side yields that
PI harms both firms L and M , thus lowering home industry profit:
∆ΠH = (π
∗∗
L + π
∗∗
M)− (π∗L + π∗M) < 0. (27)
PI hence benefits consumers, but always at the expense of local firms, regardless
of their resulting innovative activities. Weighing the magnitude of consumer gains
against producer losses reveals that:
Lemma 2 Introducing PI always reduces aggregate welfare in the home country as
∆WH = ∆CSH +∆ΠH < 0.
Proof see Appendix III. 
One solution to this dilemma could be the imposition of tariffs on those imports
whose legitimacy is the object of our discussion.18 To investigate this possibility, we
simply consider trade costs to be tariffs levied on PI. In this setting, social welfare
in H is augmented by tariff revenues
T = τ · q∗∗SH (28)
and is defined by WTH =W
∗∗
H +T . A high tariff rate increases per unit revenue, but
reduces the total quantity of imports (∂q∗∗SH/∂τ < 0). Additionally, ∂q
∗∗
SH
/∂β < 0
implies that total revenue is higher the lower the value of β (∂T/∂β < 0).
Given Lemma 2, for PI to increase home welfare it must be true that
∆WTH = T +∆WH > 0. (29)
On the one hand, only a high tariff can sufficiently reduce the loss ∆WH to
make this feasible. On the other hand, T is hump-shaped in τ . As ∂T/∂β < 0, a
relatively large degree of firm heterogeneity is a pre-requisite for tariffs to overturn
the detrimental result on welfare. We can deduce that
Proposition 3 A tariff on PI can make the international exhaustion system welfare
improving only if the technology gap between home firms is sufficiently large.
17All explicit formulation for the welfare comparison can be found in Appendix III.
18Hur and Riyanto (2006) also use trade costs to show how PI can be beneficial for the host country
in the presence of a tariff policy. Their analysis however abstracts from the role of innovation.
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Proof see Appendix III. 
The intuition behind Proposition 3 is that social welfare is higher in H under PI
when it is possible to simultaneously mitigate the damage to home firms and collect
a relatively high tariff revenue. The enforcement of tariffs by the home government
is essential to reduce the profit loss (∂ |∆ΠH | /∂τ < 0). However, as noted above, an
additional earning is necessary to make PI welfare improving. The tariff revenues
can only reach the critical level to satisfy ∆WTH > 0 for lor low values of β. The
cone-shaped area in Figure 2 represents the parametric region in which social welfare
is higher under PI when tariff revenues are taken into account.19
Figure 2: Welfare
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5 Conclusion
In this paper we have examined the consequences of an international exhaustion
system in an emerging economy. In so doing, we have based our model on the Indian
19Recall that above τˆ the foreign firm does not export to the H market.
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pharmaceutical industry, which after the Patent Act 2005 has experienced a surge
in PI arriving from markets not yet obliged by TRIPS to enforce IPR protection. A
good example is Tanzania, inferior both in terms of technology and IPR enforcement.
Such unexploited markets can serve as interesting destinations for less efficient firms
in the industry. In the Indian pharmaceutical sector firms can be broadly categorized
into two types: (i) a larger company evolving with the aim of taking a lead role on
innovation and reach the global market; (ii) a medium firms not as well endowed
with technology specializing in producing generics or incremental drugs.
We find that competition in the home market plays a major role in the R&D
decision of the large firm. Trade costs transfer the loss brought about by PI from the
large to the medium firm. This results in a less aggressive medium firm, which then
increases the incentives of the dominant competing firm to innovate. For the medium
firm, it is sales in the foreign market that plays the decisive role in its decision to
invest in R&D. When a policy favoring PI paradoxically increases its grasp over the
Southern market, the medium firm also increases its R&D efforts. This is more likely
for low degrees of firm heterogeneity, which also implicitly implies a large enough
cost advantage over the Southern firm.
As for welfare, although PI always benefits consumers through lower prices and
can increase innovation by both firms, this comes at the expense of profits in a catch
up phase where firms seek competitiveness in the global market. Although trade
costs create a form of protection against PI, they never fully compensate firms for
the losses brought about by such policy. Only when trade costs generate government
revenue, i.e. tariffs, PI may also be welfare-enhancing for the home country. This
is only a possibility in the presence of large technological asymmetry between firms,
which in turn assures sufficient revenues to overturn the welfare results.
We can conclude from our findings that in an emerging industry where the tech-
nology gap between firms is large, an international exhaustion system accompanied
by tariffs can increase innovation and welfare in the home country. These are the
actual conditions that apply to the pharmaceutical industry in India, but not in fully
developed economies such as the US or EU, justifying assorted policies observed with
regards to PI in different parts of the world.
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Appendix I
In Appendix I we report the final form values of equilibrium profits, consumer
surplus and total welfare, using (10), (8) and (9) for the PI and (17), (15) and (16)
for the no PI case.
No Parallel Import
π∗L =
137113β4−1023876β2+1966356
(1071−242β2)2 , (A1)
π∗M =
98β4−49555β2+221085
(1071−242β2)2 , (A2)
CS∗H =
2(277β2−1530)2
8(242β2−1071)2 , (A3)
W ∗H =
8042292−3291812β2+351739β4
8(1071−242β2) . (A4)
Parallel Import
π∗∗L =
26790912−4896β2[3034+1641τ+645τ2]+β4[2093927+1267554τ+471495τ2]+1057536τ(12+5τ)
12(2448−623β2)2
(A5)
π∗∗M =
8501760−108β2[21355+8408τ+10032τ2]+145β4[24τ−17]2+497664τ(11+6τ)
9(2448−623β2)2 (A6)
CS∗∗H =
8[1440−325β2−3τ(144−43β2)]2
9(2448−623β2) . (A7)
W ∗∗H =
60244992−48β2[581533+47646τ+120654τ2]+β4[3276467+215394τ+760359τ2]+62208τ(108+181τ)
12(2448−623β2)2 .
(A8)
Appendix II
In this appendix we present the differences in both quantity and investment levels
that appear in Section 4.1. The sign of the following expressions has been evaluated
in the relevant interval region β ∈ [0, 1] ∪ τ ∈ [0, τ˜ ]:20
∆qLH= −396576−18β
2(13726−44945τ)+β4(41417−104060τ)−1542240τ
2(1071−242β2)(2448−623β2) < 0, (A9)
∆qMH=− 550800−342
2(827−1824τ)+β4(19829−46464τ)−1850688τ
3(1071−242β2)(2448−623β2) < 0, (A10)
20Addional calculations and precise graphical representations for this and the following appendix
are available upon request.
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∆qMS= −β
2[12546−β2(7981−17424τ)−77112τ ]
(1071−242β2)(2448−623β2) > 0 for τ > τM , (A11)
∆xL = −49
{
[2203200−9β2(128611+26967τ)+2β4(15609τ+75307)+462672τ ]
(1071−242β2)2 · (A12)
· [44064−9β2(3479−26967τ)+2β4(3191−15609τ)−462672τ ]
(2448−623β2)2
}
> 0 for τ > τL,
∆xM =
3β2[1044378−β2(251423+52272τ)+231336τ ][12546−β2(7981−17424τ)−77112τ ]
(1071−242β2)2(2448−623β2)2
> 0 for τ > τM . (A13)
Appendix III
In this appendix we evaluate the sign of the inequalities that appear in Section
4.2. First of all:
∆CSH =
1
72
{
[1101600−18β2(37699−107868τ)+β4(111487−249744τ)−3701376τ ]
(1071−242β2)2 · (A14)
· [23574240−18β2(581461−107868τ)+β4(1146913−249744τ)−3701376τ ]
(2448−623β2)2
}
> 0,
∆ΠH= − [22552103255040−198288β
2(116908819−317210334τ−152565966τ2)]+β4Ψ−71355126528τ(964+447τ)
36(1071−242β2)2(2448−623β2)2 < 0,
(A15)
where:
Ψ=[8944586709615−36β2(43070165909−3350119771944τ−1715020497036τ2)+
+7β4(14660626163−27854561064τ−14628994380τ2)−729τ(29777635094+14803179645τ)].
Moreover,
∂|∆ΠH |
∂τ
= −9994752−144β2(32101+31962τ)+7β4(79271+83265τ)+9268992τ
6(2448−623β2)2 < 0. (A16)
Taking into account the differences on social welfare, both with and without
additional tariff revenues, we obtain:
∆WH=−6378274575360−396576β
2(15832613−30793098τ−6293653τ2)+β4Φ−142710253056τ(108+181τ)
24(1071−242β2)2(2448−623β2)2 < 0,
(A17)
where
Φ=[2298423778038−108β2(3567658219−4547941332τ−13579811366τ2)+
+β4(25794292217−25228668432τ−89059328952τ2)−1458τ(2504840178+6218960351τ)]
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and
∆WTH= −6378274575360−396576β
2(15832613−126405314τ+23842001τ2)+β4Γ−47570084352τ(1072+2109τ)
24(1071−242β2)2(2448−623β2)2 ,
(A18)
where
Γ=[2298423778038−36β2(10702974657−85448407748τ+144996813654τ2)+
+β4(25794292217−191310081776τ+305858337576τ2)−486τ(38251547402−68627567319τ)].
Finally, we prove Proposition 3 by solving for the value of τ that determines the
condition under which PI can be welfare enhancing. From (A18):
∆WTH = 0 =⇒ (A20)
τ = 23807250432−2β
2(9011812464−2303178705β2+197634382β4)±√2Ω(2448−623β2)
6(14577408−7150752β2+870439β4)(1071−242β2) ,
where
Ω=743646624768−2571277828320β2+β4(2017891648980−455187836484β2+27726926171β4).
More specifically,
∆WTH ≥ 0 when t ∈ [τ−, τ+] ,
where τ− and τ+ are the two threshold values coming from (A20). They can be
represented in β ∈ [0, 1], giving rise to the cone represented in Figure 3.
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